Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does Advagene Biopharma Co. Ltd. (6709) operate in?
Advagene Biopharma Co. Ltd. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Advagene Biopharma Co. Ltd. (6709) current stock price?
As of the latest data, Advagene Biopharma Co. Ltd. stock price is NT$25.90, with a previous close of NT$26.30. Advagene Biopharma Co. Ltd. lost -NT$0.40 in the last trading session, representing a -1.52% loss.
What is Advagene Biopharma Co. Ltd. (6709) current market capitalization?
Advagene Biopharma Co. Ltd. market cap is approximately 1.80 billion.
What is Advagene Biopharma Co. Ltd. (6709) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.14.
Does Advagene Biopharma Co. Ltd. (6709) pay dividends?
No. Advagene Biopharma Co. Ltd. does not pay a dividend.
What is Advagene Biopharma Co. Ltd. (6709) beta (volatility) score?
Advagene Biopharma Co. Ltd. has a beta of 0.619, indicating lower volatility than the overall market.